{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:07:54Z","timestamp":1778803674806,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004071","name":"Khon Kaen University","doi-asserted-by":"publisher","award":["590004"],"award-info":[{"award-number":["590004"]}],"id":[{"id":"10.13039\/501100004071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004071","name":"Khon Kaen University","doi-asserted-by":"publisher","award":["6200045"],"award-info":[{"award-number":["6200045"]}],"id":[{"id":"10.13039\/501100004071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.dmpk.2021.100442","type":"journal-article","created":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T01:44:54Z","timestamp":1640396694000},"page":"100442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Inhibitory effects of non-steroidal anti-inflammatory drugs on human liver microsomal morphine glucuronidation: Implications for drug-drug interaction liability"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-468X","authenticated-orcid":false,"given":"Verawan","family":"Uchaipichat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dmpk.2021.100442_bib1","first-page":"344","article-title":"Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations","volume":"24","author":"Hasselstrom","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100442_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in\u00a0vitro-in\u00a0vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metab Rev"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100442_bib3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.dmpk.2021.100442_bib4","doi-asserted-by":"crossref","first-page":"107689","DOI":"10.1016\/j.pharmthera.2020.107689","article-title":"Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in\u00a0vitro and UDP-glucuronosyltransferase reaction phenotyping","volume":"218","author":"Miners","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmpk.2021.100442_bib5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/dmd.31.9.1125","article-title":"Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7\u22172 polymorphism","volume":"31","author":"Court","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100442_bib6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/dmd.107.019281","article-title":"Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties","volume":"36","author":"Ohno","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmpk.2021.100442_bib7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/dmd.31.9.1086","article-title":"Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7","volume":"31","author":"Stone","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100442_bib8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1533-2500.2001.01025.x","article-title":"Cancer pain: progress since the WHO guidelines","volume":"1","author":"Burton","year":"2001","journal-title":"Pain Pract"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100442_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2133\/dmpk.22.103","article-title":"Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine","volume":"22","author":"Hara","year":"2007","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100442_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2125.2009.03469.x","article-title":"Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs","volume":"68","author":"Knights","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100442_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00228-006-0241-9","article-title":"Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes","volume":"63","author":"Mano","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100442_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1124\/jpet.110.167916","article-title":"In\u00a0vitro-in\u00a0vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans","volume":"334","author":"Raungrut","year":"2010","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100442_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.dmpk.2017.10.005","volume":"33","author":"Uchaipichat","year":"2018","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100442_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in\u00a0vivo inhibitory interactions involving glucuronidated drugs from in\u00a0vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.dmpk.2021.100442_bib15","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1124\/dmd.111.039727","article-title":"Effects of ketamine on human UDP-glucuronosyltransferases in\u00a0vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation","volume":"39","author":"Uchaipichat","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100442_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.dmpk.2021.100442_bib17","series-title":"In\u00a0vitro drug interaction studies - cytochrome P450 enzyme - and transporter-mediated drug interactions: guidance for Industry","year":"2020"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100442_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/ecp.13.4","article-title":"Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach","volume":"6","author":"Yeo","year":"2013","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2021.100442_bib19","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100442_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/psp4.12144","article-title":"Characterization of contributing factors to variability in morphine clearance through PBPK modeling implemented with OCT1 transporter","volume":"6","author":"Emoto","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2021.100442_bib21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.118.080523","article-title":"Abundance of phase 1 and 2 drug-metabolizing enzymes in alcoholic and hepatitis C cirrhotic livers: a quantitative targeted proteomics study","volume":"46","author":"Prasad","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100442_bib22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/jpet.113.212258","article-title":"Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies","volume":"349","author":"Chau","year":"2014","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100442_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.106.118216","article-title":"Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in\u00a0vitro-in\u00a0vivo extrapolation","volume":"321","author":"Rowland","year":"2007","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100442_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/cpt.905","article-title":"Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children","volume":"104","author":"Zhou","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100442_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/07420529309059703","article-title":"Pharmacokinetics of single-dose administration of naproxen at 10:00 and 22:00 hours","volume":"10","author":"Rao","year":"1993","journal-title":"Chronobiol Int"},{"issue":"5","key":"10.1016\/j.dmpk.2021.100442_bib26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF00558244","article-title":"Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids","volume":"35","author":"Neuvonen","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.dmpk.2021.100442_bib27","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in\u00a0vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100442_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/dmd.106.011569","article-title":"Evaluation of cryopreserved human hepatocytes as an alternative in\u00a0vitro system to microsomes for the prediction of metabolic clearance","volume":"35","author":"Brown","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2021.100442_bib29","first-page":"e10","article-title":"From pediatric covariate model to semiphysiological function for maturation: Part II-sensitivity to physiological and physicochemical properties","volume":"1","author":"Krekels","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100442_bib30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/clpt.1990.2","article-title":"Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide","volume":"47","author":"Osborne","year":"1990","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100442_bib31","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1208\/s12249-010-9518-5","article-title":"Formulation development of morphine sulfate sustained-release tablets and its bioequivalence study in healthy Thai volunteers","volume":"11","author":"Preechagoon","year":"2010","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100442_bib32","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100442_bib33","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.dmpk.2021.100442_bib34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bcp.2013.06.019","article-title":"Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration","volume":"86","author":"Tzvetkov","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100442_bib35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/jpet.102.038992","article-title":"Extrapolation of diclofenac clearance from in\u00a0vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide","volume":"303","author":"Kumar","year":"2002","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"1\u20132","key":"10.1016\/j.dmpk.2021.100442_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2012.03.019","article-title":"Prediction of the human oral bioavailability by using in\u00a0vitro and in silico drug related parameters in a physiologically based absorption model","volume":"429","author":"Paixao","year":"2012","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100442_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.2005.02446.x","article-title":"S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen","volume":"60","author":"Bowalgaha","year":"2005","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmpk.2021.100442_bib38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/j.1552-4604.1993.tb01926.x","article-title":"Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration","volume":"33","author":"Mueller","year":"1993","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2021.100442_bib39","series-title":"Mefenamic acid","year":"2008"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100442_bib40","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/j.1552-4604.1987.tb03024.x","article-title":"A\u00a0multiple-dose pharmacokinetic comparison of naproxen as a once-daily controlled-release tablet and a twice-daily conventional tablet","volume":"27","author":"Ling","year":"1987","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100442_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1208\/s12248-020-00541-1","article-title":"Application of model informed precision dosing to address the impact of pregnancy stage and CYP2D6 phenotype on foetal morphine exposure","volume":"23","author":"Badaoui","year":"2021","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100442_bib42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bja\/aei007","article-title":"Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma","volume":"94","author":"Kotb","year":"2005","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100442_bib43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2125.1990.tb03638.x","article-title":"The metabolism and bioavailability of morphine in patients with severe liver cirrhosis","volume":"29","author":"Hasselstrom","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmpk.2021.100442_bib44","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.bcp.2007.01.030","article-title":"Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7","volume":"73","author":"Gaganis","year":"2007","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100442_bib45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/bdd.1933","article-title":"Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS\/MS","volume":"36","author":"Joo","year":"2015","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100442_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/toxsci\/61.1.49","article-title":"Characterization of rat and human UDP-glucuronosyltransferases responsible for the in\u00a0vitro glucuronidation of diclofenac","volume":"61","author":"King","year":"2001","journal-title":"Toxicol Sci"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100442_bib47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In\u00a0vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2021.100442_bib48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev.pharmtox.38.1.461","article-title":"Quantitative prediction of in\u00a0vivo drug clearance and drug interactions from in\u00a0vitro data on metabolism, together with binding and transport","volume":"38","author":"Ito","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.dmpk.2021.100442_bib49","series-title":"Mefenamic acid","year":"2021"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100442_bib50","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/03602539608994011","article-title":"The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine","volume":"28","author":"Milne","year":"1996","journal-title":"Drug Metab Rev"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134743672100063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134743672100063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:13:34Z","timestamp":1778800414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134743672100063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":50,"alternative-id":["S134743672100063X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100442","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of non-steroidal anti-inflammatory drugs on human liver microsomal morphine glucuronidation: Implications for drug-drug interaction liability","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100442"}}